Calvo Elected for Second Term at EMA
Dr. Gonzalo Calvo has been re-elected by the Healthcare Professionals’ Working Party (HCPWP) of the European Medicines Agency (EMA) as its co-chair.
The Healthcare Professionals' Working Party (HCPWP) of the European Medicines Agency (EMA) has re-elected Dr. Gonzalo Calvo as its co-chair.
Calvo, a physician and consultant in clinical pharmacology from Barcelona, Spain, has extensive experience in medicines regulation, including nearly 10 years as a member of EMA’s Committee for Medicinal Products for Human Use (CHMP).
“My aim is to consolidate the work initiated and open new paths to strengthen the role and impact of healthcare professionals in regulatory activities, securing fast and safe access to new medicines,” said Calvo. “Close collaboration with the patients and consumers’ working group has been instrumental for the progress of HCPWP work. I do not see any other way forward than enhancing our interaction with patients and consumers.”
Together with Isabelle Moulon, Head of the Public Engagement Department at EMA, he will co-chair HCPWP for the next three years.
No decision was reached, however, on the new co-chair of the Patients' and Consumers' Working Party (PCWP).
The main role of the PCWP and the HCPWP is to provide recommendations to EMA and its scientific committees on all matters of interest to either patients and consumers or healthcare professionals in relation to medicines, as well as to monitor interactions between the agency and patients, consumers and healthcare professionals.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
